Floatz Rating
B56/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05672095CT.gov Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | — | Withdrawn | — | — | — |
NCT04673448CT.gov Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT03586661CT.gov Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | City of Hope Medical Center | P1/2 | B · 56 |
| Carboplatin | Women's Hospital School Of Medicine Zhejiang University | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P3 | BB |
| Tamoxifen | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | BB |
| Cyclophosphamide | Mayo Clinic | P2 | BB |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | Brigham and Women's Hospital | P3 | BB |
| Atezolizumab | Ronald Buckanovich | P2/3 | BB |
+42 more in the Fallopian Tube Carcinoma cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niraparib in Fallopian Tube Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-fallopian-tube-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →